Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28389560 | 0.85 | LMNA (0.40) | MEN1KMT2AGRM1TDP1CYP1A2 | |
| SCHEMBL6064118 | 0.85 | TDP1 (0.39) | MEN1KMT2AGRM1TDP1CYP1A2 | |
| SCHEMBL6841351 | 0.85 | TDP1 (0.39) | MEN1KMT2AGRM1TDP1CYP1A2 | |
| SCHEMBL6307444 | 0.83 | MEN1 (0.41) | MEN1KMT2ASRCTRPA1LMNA | |
| SCHEMBL508992 | 0.83 | TSHR (0.50) | MEN1KMT2AGRM1TDP1CYP1A2 | |
| SCHEMBL1424025 | 0.80 | ACHE (0.47) | MEN1KMT2ATDP1SRCSMN1; SMN2 | |
| SCHEMBL509062 | 0.80 | SRC (0.47) | MEN1KMT2ATDP1SRCSMN1; SMN2 | |
| SCHEMBL6834772 | 0.80 | SMN1; SMN2 (0.42) | MEN1KMT2ACYP1A2SMN1; SMN2HTT | |
| SCHEMBL7864024 | 0.80 | MEN1 (0.44) | MEN1KMT2AGRM1TDP1CYP1A2 | |
| SCHEMBL11836947 | 0.79 | PPARG (0.46) | MEN1KMT2AGRM1TDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016147132-A1 | A PROCESS FOR THE PREPARATION OF DROXIDOPA | Piramal Enterprises Limited (IN) | 2016-09-22 | — | — | WO | disclosed |
| US-8507410-B2 | Pyridazinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8470738-B2 | Pyridazinone compound and herbicide containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2188264-B1 | PYRIDAZINONE COMPOUND AND HERBICIDE CONTAINING THE SAME | SUMITOMO CHEMICAL CO (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100216642-A1 | PYRIDAZINONE COMPOUND AND HERBICIDE CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | C5, C1S, WEE1 | MEN1 806/4885KMT2A 4005/4885GRM1 1320/4885 |
| US-20100216642-A1 | PYRIDAZINONE COMPOUND AND HERBICIDE CONTAINING THE SAME | WEE1, WEE2, CBR3 | MEN1 2158/4885KMT2A 1764/4885GRM1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.